权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Association of TFPI with antemortem dementia and postmortem micro brain infarcts

TFPI 与生前痴呆和死后微脑梗死的关联

基本信息

批准号：
8703779
负责人：
Susan Antone Maroney
金额：
$ 12.27万
依托单位：
VERSITI WISCONSIN, INC.
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-19 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8703779
关键词：
Affect Age Aging Alzheimer&apos s Disease American Anticoagulants Antigens Apolipoprotein E Asians Automobile Driving Autopsy Binding Biochemical Biological Blood Platelets Blood Vessels Blood coagulation Brain Brain Pathology Cardiovascular Diseases Cerebrum Clinical Coagulants Coagulation Process DNA Data Databases Deep Vein Thrombosis Dementia Deposition Development Disease E protein Employee Strikes Endothelial Cells Endothelium Enrollment Event Exons Factor Xa Family Fibrin Financial cost Genes Genetic Polymorphism Genotype Heart Histopathology Human Individual Infarction Intravascular Thrombus Formation Japanese American Japanese Population Laboratories Lead Linear Regressions Lipoprotein Binding Lipoproteins Logistic Regressions Low-Density Lipoproteins Lung Measurement Measures Memory Loss Modeling Mus National Heart, Lung, and Blood Institute Nucleic Acid Regulatory Sequences Organ Pathogenesis Pathology Patients Peptide Hydrolases Physiological Plasma Plasma Proteins Population Prevalence Promoter Regions Protein S Protein S Deficiency Proteins Reaction Risk Risk Factors Sampling Severities Specimen Structural Genes System TFPI Techniques Test Result Thrombin Thromboplastin Thrombosis Time Translating United States Variant Vascular Dementia apolipoprotein E-4 base cognitive function cohort human disease in utero inhibitor/antagonist innovation interest men mouse model novel prevent programs repository vascular factor

项目摘要

DESCRIPTION (provided by applicant): In 2001, the world wide number of patients with dementia was approximately 24 million and is expected to increase to 84 million people by the year 2040. Vascular factors appear to be a major component to dementia including those factors involving coagulation. Tissue Factor Pathway Inhibitor (TFPI) is the primary physiological inhibitor of tissue factor, the initiator of clotting after a blood vessel has been damaged, and FXa, a major component of the clotting system that produces a large amount of thrombin resulting in clot formation. TFPI is found in endothelial cells, in platelets or in plasma. In plasa it is either bound to the plasma lipoproteins, predominately LDL, with less anti-coagulant activity or in an active free unbound form. Another anti-coagulant protein, Protein S (PS), directly interacts with TFPI promoting an enhanced inhibition of FXa. Mouse models of either tfpi-/- and pros-/- mice die in utero and have intravascular fibrin clots in the brain. Normal variations in plasma TFPI and PS concentrations are strongly influenced by polymorphisms in their respective structural genes. Several TFPI polymorphisms and PS polymorphisms have been associated with deep vein thrombosis, however, it is not known if polymorphisms of these two interactive proteins cause micro- brain infarcts and dementia. Preliminary data demonstrate that mouse models lacking either endothelial cell or platelet TFPI produce intravascular fibrin micro-clots preferentially in the brain suggesting a critical amount of TFPI and /or PS are necessary to prevent abnormal clotting in the brain. We have techniques available within our laboratory to translate the data from mouse models to the disease of human dementia using DNA and plasma specimens from the NHLBI BioLINCC Honolulu Heart Project consisting of a homogenous population of Japanese and Japanese-Americans residing in Honolulu. Of interest are the 404 individuals with and without dementia who later came to autopsy in which brain pathology was characterized. In Aim1 we will sequence the exons and 5' promoter region of the TFPI gene in all individuals to identify any polymorphisms and correlate the polymorphisms with TFPI plasma concentrations and anti-FXa activity. In Aim2 we will identify individuals with the PS 196K>E polymorphism which is found uniquely in the Japanese population and correlate this polymorphism with the PS plasma concentration and anti-thrombotic activity. In Aim3 we will correlate the TFPI plasma concentrations and activity with lipoprotein levels and ApoE genotype of the cohort which have been previously determined. At the conclusion of these studies, we will have identified TFPI polymorphisms associated with dementia and determined the TFPI plasma concentrations and activity with the polymorphisms, determined the relationship of the 196K>E PS polymorphism to dementia and correlated the associated plasma concentration and activity of PS with dementia, and determined the relationship of TFPI to ApoE. Finally, other risk factors of cardiovascular disease found within the BioLINCC database will be used in a linear regression model to determine the significance of TFPI and PS on the pathogenesis of dementia.

描述（由申请人提供）：2001年，全球痴呆症患者人数约为2400万，预计到2040年将增加到8400万。血管因素似乎是痴呆的主要组成部分，包括那些涉及凝血的因素。组织因子途径抑制剂（Tissue Factor Pathway Inhibitor， TFPI）是组织因子（Tissue Factor）的主要生理性抑制剂，是血管受损后凝血的启动剂；FXa是凝血系统中产生大量凝血酶导致凝块形成的主要成分。TFPI存在于内皮细胞、血小板或血浆中。在血浆中，它要么与血浆脂蛋白结合，主要是低密度脂蛋白，抗凝活性较低